Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To evaluate the long-term safety and efficacy of deferasirox (a once-daily oral iron chelator), patients with SCD completing a 1-year, Phase II,...

Descripción completa

Detalles Bibliográficos
Autores principales: Vichinsky, Elliott, Bernaudin, Françoise, Forni, Gian Luca, Gardner, Renee, Hassell, Kathryn, Heeney, Matthew M, Inusa, Baba, Kutlar, Abdullah, Lane, Peter, Mathias, Liesl, Porter, John, Tebbi, Cameron, Wilson, Felicia, Griffel, Louis, Deng, Wei, Giannone, Vanessa, Coates, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Red Cells and Iron
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170481/
https://www.ncbi.nlm.nih.gov/pubmed/21592110
http://dx.doi.org/10.1111/j.1365-2141.2011.08720.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170481/
https://www.ncbi.nlm.nih.gov/pubmed/21592110
http://dx.doi.org/10.1111/j.1365-2141.2011.08720.x

Ejemplares similares